Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Biosimilar infliximab could offset access inequities in East European Crohn's patients

This article was originally published in Scrip

Executive Summary

Introduction of biosimilar Remicade (infliximab) to treat Crohn's disease is expected to provide substantial savings in six central and east European (CEE) countries. As Johnson & Johnson revealed the impact that the launch of Celltrion's Remsima is having on sales of Remicade, Hungarian health economists are forecasting that budget savings from use of the biosimilar, priced at just a 25% discount, could fund treatment in almost a third more patients.





Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts